Placental Transcriptomic Analysis in Retinopathy of Prematurity Reactivation after Anti-VEGF Treatment

Retinal Diseases

A meta-analysis of intravitreal ranibizumab versus laser photocoagulation for the treatment of retinopathy of prematurity

Ophthalmol Retina

Baiad AA, Sun C, Yin GS, Popovic MM, Muni RH, Mireskandari K, Kertes PJ

doi: 10.1016/j.oret.2025.01.012

Retinal Diseases

Treatment Patterns and Long-Term Outcomes with Anti-VEGF Therapy for Retinal Vein Occlusion: An Analysis of the Vestrum Database

Ophthalmol Retina

Ip M, Modi Y, Fekrat S, Gibson K, Boucher N, Arrisi P, Ishii F, Liu Y, Paris LP, Fenech M, Chi GC

doi: 10.1016/j.oret.2025.05.025

Retinal Diseases

Bilateral Anti VEGF on Same Day-Investigation on Safety in Retinopathy of Prematurity (BASISROP)- A Multicenter retrospective study

Ophthalmol Retina

Gangwe AB, Agrawal A, Jalali S, Banker A, Padhi T, Shah P, Rajan RP, Kulkarni S, Shah S, Singhal R, Das P, Kapoor A, Vinekar A, Bavaskar S, Vedantham V, Sanghi G, Bhattacharya S, Banker A, Gaikwad A, Shrivastava S, Nayak S, Panchal B, Agrawal D, Azad RV

doi: 10.1016/j.oret.2024.11.004

Macular DiseasesRetinal Diseases

Persistence of Retinal Fluid after Anti-VEGF treatment for neovascular age-related macular degeneration: A Systematic Review and Meta-Analysis

Ophthalmol Retina

Ting Yap DW, Jyn Tan BK, Yi Chong KT, Wong TY, Gemmy Cheung CM

doi: 10.1016/j.oret.2025.01.010

Blindness and Vision ImpairmentRetinal Diseases

Retinopathy of Prematurity: Incidence, Risk Factors, and Treatment Outcomes in a Tertiary Care Center

J Clin Med

Blazon MN, Rezar-Dreindl S, Wassermann L, Neumayer T, Berger A, Stifter E

doi: 10.3390/jcm13226926

Retinal Diseases

Retinal vascularization rate predicts retinopathy of prematurity and remains unaffected by low-dose bevacizumab treatment

Am J Ophthalmol

Chang E, Josan A, Purohit R, Aslam SA, Hartley C, Patel CK, Xue K

doi: 10.1016/j.ajo.2025.02.040

Macular Diseases

Real-World 10-Year Outcomes of Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration: A Meta-Analysis

Clin Exp Ophthalmol

Spooner K, Broadhead G, Fraser-Bell S, Hong T, Wong JG, Chang AA

doi: 10.1111/ceo.14559

Macular Diseases

Incidence and reasons for discontinuation of anti-VEGF treatment in neovascular age-related macular degeneration

Br J Ophthalmol

Borrelli E, Foti C, Ulla L, Porreca A, Introini U, Grassi MO, Viggiano P, Peronetti M, Toscani R, Boscia G, Termite AC, Gennaro C, Marolo P, Boscia F, Bandello F, Reibaldi M

doi: 10.1136/bjo-2024-326152

Macular Diseases

Choroidal thickness after anti-VEGF in typical neovascular age-related macular degeneration - A systematic review and meta-analysis

Surv Ophthalmol

Hoven E, Michelet JT, Vettore MV, Lagali N

doi: 10.1016/j.survophthal.2024.09.011

Related content

A meta-analysis of intravitreal ranibizumab versus laser photocoagulation for the treatment of retinopathy of prematurity

Treatment Patterns and Long-Term Outcomes with Anti-VEGF Therapy for Retinal Vein Occlusion: An Analysis of the Vestrum Database

Bilateral Anti VEGF on Same Day-Investigation on Safety in Retinopathy of Prematurity (BASISROP)- A Multicenter retrospective study

Persistence of Retinal Fluid after Anti-VEGF treatment for neovascular age-related macular degeneration: A Systematic Review and Meta-Analysis

Retinopathy of Prematurity: Incidence, Risk Factors, and Treatment Outcomes in a Tertiary Care Center

Retinal vascularization rate predicts retinopathy of prematurity and remains unaffected by low-dose bevacizumab treatment

Real-World 10-Year Outcomes of Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration: A Meta-Analysis

Incidence and reasons for discontinuation of anti-VEGF treatment in neovascular age-related macular degeneration

Choroidal thickness after anti-VEGF in typical neovascular age-related macular degeneration - A systematic review and meta-analysis